COVID-19 Residual Biobank (Enrolling by Invitation Only)

Overview

About this study

The purpose of this study is to collect residual (waste) blood, urine, and stool specimens remaining from clinician order testing and corresponding clinical and patient provided data from COVID-19 patients with confirmed or suspected infection with the novel SARS-CoV-2 virus to enable high quality research. 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Mayo Clinic patients diagnosed with or suspected to have COVID-19 (infection with SARS-CoV-2).

Exclusion Criteria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Richard Kennedy, Ph.D.

Closed for enrollment

Contact information:

COVID-19 Biobank (enterprise)

(507) 293-3996

COVID19biobank@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Christopher Marquez, M.D.

Closed for enrollment

Contact information:

COVID-19 Biobank (enterprise)

(507) 293-3996

COVID19biobank@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Erin Kaleta, Ph.D.

Closed for enrollment

Contact information:

COVID-19 Biobank (enterprise)

(507) 293-3996

COVID19biobank@mayo.edu

More information

Publications

Publications are currently not available